Article

Cardiac Intervention Guidelines Get Update

Author(s):

The American College of Cardiology (ACC) has had a change of heart. The group is now recommending doctors treating heart attack patients for arterial blockages should treat lesions in both cardiac arteries, not just the "culprit" artery that led to the MI.

The American College of Cardiology (ACC) has had a change of heart.

The group is now recommending doctors treating heart attack patients for arterial blockages should treat lesions in both cardiac arteries, not just the “culprit” artery that led to the MI.

In a statement Sept. 22, the ACA cited new information—reported Sept. 5 by HCPLive.com—from a UK study showing that it pays to do the more extensive procedure.

Reporting on a study known as CvLPRIT, principal investigator Anthony Gershlick, MD, said performing PCI to remove lesions in non-involved arteries as well resulted in a 55% reduction in major adverse cardiac events (MACE). The full name of the study is “Complete Versus Lesion only Primary-PCI trial”.

In announcing the change, the ACC said “in the last two years, new science has emerged showing potential improvements for some patients in their overall outcomes as a result of complete revascularization”. Earlier studies were inconclusive, the ACC said.

“Science is not static but rather constantly evolving,” said ACC President Patrick T. O’Gara, MD, FACC. “As such, one of the ACC’s primary roles is to stay abreast of this evolution and provide cardiovascular professionals and patients with the most up-to-date information on which to base decisions about the most appropriate and necessary treatment. The newest findings regarding coronary revascularization are great examples of science on the move, and we are responding accordingly.”

The ACC also noted that results from the CvLPRIT study reinforce data from another trial, the Preventive Angioplasty in Myocardial Infarction (PRAMI) Trial released in 2013, that show stenting all coronary arteries with major stenoses improves outcomes.

In its statement, the ACC concluded that since “some questions remain about the exact timing of the procedures; whether certain patients benefit versus others; whether fractional flow reserve might guide decisions; and the role of patient complexity and hemodynamic stability, there is additional need for further data across larger populations”.

Related Videos
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Nathan D. Wong, MD, PhD: Growing Role of Lp(a) in Cardiovascular Risk Assessment | Image Credit: UC Irvine
Laurence Sperling, MD: Expanding Cardiologists' Role in Obesity Management  | Image Credit: Emory University
Laurence Sperling, MD: Multidisciplinary Strategies to Combat Obesity Epidemic | Image Credit: Emory University
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orly Vardeny, PharmD: Finerenone for Heart Failure with EF >40% in FINEARTS-HF | Image Credit: JACC Journals
Matthew J. Budoff, MD: Impact of Obesity on Cardiometabolic Health in T1D | Image Credit: The Lundquist Institute
Matthew Weir, MD: Prioritizing Cardiovascular Risk in Chronic Kidney Disease | Image Credit: University of Maryland
Erin Michos, MD: HFpEF in Women and Sex-Specific Therapeutic Approaches | Image Credit: Johns Hopkins
© 2024 MJH Life Sciences

All rights reserved.